Trial
NCT06955169
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
Phase IISUSPENDEDREGULATORYConfidence: MEDIUM
Sponsor
RTOG Foundation, Inc.
Collaborators
Novartis Pharmaceuticals
Condition
Intracranial Meningioma
Intervention
[177Lu]Lu-DOTATATE
Why stopped
Recent FDA feedback requiring a study amendment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-22